IBT is developing novel targeted biologic products for treatment and prophylaxis of multiple bacteria and bacterial toxins. The technology platform for our targeted biologic products uses cell wall targeting domains (CWTs) of lysins that have specificity and high affinity for the cell walls of selected bacterial pathogens.
For antibody applications, IBT has developed the “Infection Site Targeted Antitoxin Antibodies (ISTAbs) in which CWTs are linked to antibodies, enabling targeting directly to infection sites. In vitro data show activity against bacteria including S. aureus and C. difficile and others.
For targeted immunotherapy applications, IBT has developed the “Infection Site Targeted Universal Bridging Antigen” (ISTUBA), an instant vaccine broadly applicable for post exposure protection. This technology redirects an existing immune response to a “Bridging Antigen” towards new invading pathogen. In vitro data show activity against bacteria including S. pneumoniae and others.
The goal of IBT’s Targeted Biologics program is to develop practical product candidates for selected high-priority bacterial diseases to overcome the emerging problem of multidrug resistance. The next step in the program is to conduct further characterization and evaluation of the candidates, optimize leads and proceed to animal studies.